7 January 2016 - Acerus Pharmaceuticals Corporation today announced the Health Canada approval of Natesto, the first and only nasal gel for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

For more details, go to: http://www.businesswire.com/news/home/20160107006320/en/